



S9 Fig. Impact of *PIK3CA/AKT1* mutation on the invasive disease-free survival (iDFS) and overall survival (OS) of breast cancer patients with stage I-III and at least 5-year follow-up. Kaplan-Meier survival analysis; p-values calculated using a log-rank analysis. Estimated iDFS and OS by mutant status: iDFS (A) and OS (B) for all patients (n=296) with wild-type (WT) and mutant (MT) of *PIK3CA/AKT1*; iDFS (C) and OS (D) for estrogen receptor (ER) positive patients (n=210) with WT and MT of *PIK3CA/AKT1*; iDFS (E) and OS (F) for human epidermal growth factor receptor 2 (HER2) negative patients (n=210) with WT and MT of *PIK3CA/AKT1*; iDFS (G) and OS (H) for Ki67 high patients (n=240) with WT and MT of *PIK3CA/AKT1*.